Compare Novo Nordisk A/S (NVO) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.25. The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| NVO | USIG | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $52.69 |
52-Week Low | $35.29 | $50.18 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
USIG trades at $50.25, up 0.14% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. Recent news includes a transaction with Tiptree Inc. and increased institutional interest from Bank of New York Mellon Corp. The stock shows consistent dividend payments, with three recent distributions totaling $0.62 per share through mid-2026.
The outlook remains cautious due to weak technical momentum and limited fundamental data visibility. Risks include reliance on corporate bond market stability and competitive pressures in the insurance sector. Analyst sentiment is neutral, with institutional accumulation suggesting long-term confidence amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
